UW Adult COVID-19 Convalescent Plasma Program: In conjunction with the National Consortium for COVID-19 Convalescent Plasma and the Mayo Clinic Emergency Access Protocol, and in partnership with local and national representatives of the American Red Cross, we are developing a program to: identify donors; transport and store convalescent plasma; and effectively identify and treat COVID-19 patients.
UW Pediatric COVID-19 Convalescent Plasma Program: Using our UW Pediatric Compassionate Use COVID-19 Convalescent Plasma Protocol, we are evaluating the effectiveness of convalescent plasma in children infected with SARS-CoV-2 who have been hospitalized for the virus. Using the FDA Emergency Investigational New Drug (EIND) application we are able to evaluate, treat and follow up with patients as young as one-month-old.
UW-Regeneron Reg-CoV-2 Antispike Monoclonal Antibody Cocktail: In partnership with Regeneron Pharmaceuticals, and with funding provided by Operation Warp Speed (OWS), we are evaluating the safety and effectiveness of two non-competing monoclonal antibodies to the spike protein on SARS-CoV-2. Three separate double-blinded, randomized, placebo-controlled studies allow us to evaluate this cocktail on hospitalized patients, outpatient individuals and household contacts of patients with COVID-19. If effective, the antibody cocktail will prevent attachment of the virus and entry into cells
UW-Astra Zeneca COVID-19 Vaccine Trial: In partnership with the bio-pharmaceutical company Astra Zeneca and Oxford University, we are testing the safety and efficacy of AZ1222, an OWS-sponsored COVID-19 vaccine as part of a worldwide phase III clinical trial. 30,000 patients will be evaluated in a double-blind, randomized, placebo-controlled study. Results and outcomes will be evaluated in real-time in order to rapidly assess the safety and effectiveness of this method of conferring active immunity.